American Century Companies Inc. Has $35.15 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

American Century Companies Inc. raised its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 63.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 756,352 shares of the company’s stock after purchasing an additional 293,751 shares during the quarter. American Century Companies Inc. owned approximately 1.27% of Twist Bioscience worth $35,148,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. ARK Investment Management LLC lifted its stake in shares of Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after purchasing an additional 237,772 shares during the period. State Street Corp increased its holdings in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after buying an additional 532,040 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after buying an additional 26,145 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on TWST shares. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Robert W. Baird raised their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $40.36 on Friday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average price of $45.15 and a 200-day moving average price of $45.33. The company has a market cap of $2.41 billion, a PE ratio of -11.94 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) EPS. Equities analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Adam Laponis sold 5,886 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,726 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the transaction, the chief executive officer now directly owns 660,966 shares in the company, valued at $27,549,062.88. This trade represents a 0.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,799 shares of company stock worth $1,593,944. 3.01% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.